AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

we should understand the company’s fundamentals and its strengths and weaknesses to better analyze how to play the stock after the recent price dip. ABBV’s Successful New Drugs — Skyrizi and ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (NYSE:ABBV) with a Outperform ...

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price suggests a potential upside of 22.02% from the company’s previous close. ABBV has been the ...

The firm currently has an overweight rating on the stock. Other equities analysts have also recently issued research reports about the company. Piper Sandler boosted their price target on AbbVie ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...